Today's story
AbbVie’s Zumilokibart Hits EASI-75 Goal in Phase 2 Eczema Trial
At EADV 2026, long-term ADlong results showed sustained efficacy and safety with lebrikizumab through week 108, with 92.9% of participants achieving EASI-75. Separately, AbbVie’s Phase 2 trial found all zumilokibart doses beat placebo on the week-16 EASI-75 endpoint, and the mid-dose regimen was selected for Phase 3 development.
Health · 12 sources · Oct 1, 2026Read it
The journal
Open the journal →The conversation starts in the journal — be the first to post.
About AbbVie
AbbVie Inc., also known as AbbVie, is an American pharmaceutical company headquartered in North Chicago, Illinois. AbbVie produces drugs to treat a wide range of medical issues.
Everything about AbbVie →- Country
- United States
- Headquarters
- North Chicago
- Inception
- April 10, 2012
- Website
- http://www.abbvie.com